World Trade Organization (WTO) members, including the United States, are considering waiving commitments to honor certain intellectual property (IP) rights on COVID-19 treatments, following a harmful and unnecessary decision to do the same for COVID-19 vaccines. This is referred to as the TRIPS waiver.
Any expansion of the TRIPS waiver would:
- Compromise global public health and harm patients
- Cede American IP to foreign countries, sending research and manufacturing jobs overseas
- Undercut American innovation and jeopardize our ability to respond to future pandemics
- Harm global collaboration and undermine U.S. leadership in the biopharmaceutical sector
Biopharmaceutical manufacturers are already sharing their IP and remain committed to providing timely global access to safe and effective COVID-19 vaccines and treatments. There is no supply shortage for COVID-19 medicines. In fact, supply exceeds demand for vaccines and treatments.
Global collaboration is fueling medicine production and access. According to Airfinity, an international data provider, 140 voluntary licensing and manufacturing agreements for COVID-19 treatments have been signed since the start of the pandemic, covering more than half the world’s population, to ensure that more than 125 low- and middle-income countries can access needed medical innovation.
The global IP system enabled America’s world-leading biopharmaceutical industry to innovate and produce safe and effective vaccines and treatments in record time.
Policymakers should reject any expansion of the TRIPS waiver and focus on last-mile distribution and administration challenges around the world to make a real impact.
To read more about the harms of TRIPS waiver expansion, click here.
Megan Van Etten
Megan Van Etten is Vice President of Public Affairs. She is responsible for leading the association’s public affairs efforts on international issues, including trade, intellectual property and access to medicines. Prior to joining PhRMA, Megan was director of media and external communications at the U.S. Chamber of Commerce and communications director at the Beer Institute. She has also worked as a communications consultant for global public relations firms. When not at the office, Megan enjoys exploring new Washington, D.C. restaurants and traveling with her husband and friends.
Megan Van Etten
Updated Analysis Underscores the Need for Brazil to Address Patent Backlogs
How post-approval innovation keeps delivering for patients
Tariffs on medicines would harm American competitiveness, industry and patients
Strong Trade Policies Protect American Workers and Biopharmaceutical Innovation
The dangers of expanding the TRIPS waiver
Coronavirus
IP Explained
Patents
Trade
TRIPS Waiver
The dangers of expanding the TRIPS waiver
The dangers of expanding the TRIPS waiver